Silver Book Fact

Early Gene Therapy Studies Show Promise for Parkinson’s Disease

Fact image

Lopes J. AXO-Lenti-PD Gene Therapy Shows Benefits in 2 Advanced Parkinson’s Patients in Phase 1/2 Trial. Parkinson's News Today. March 14 2019. https://parkinsonsnewstoday.com/2019/03/14/axo-lenti-pd-gene-therapy-shows-benefits-2-patients-phase-1-2-trial/. Accessed June 11, 2019

Christine C, Bankiewicz K, Van Laar A, Richardson R, et al. Magnetic Resonance Imaging-Guided Phase 1 Trial of Putanimal AADC Gene Therapy for Parkinson’s Disease. Ann Neurol. 2019; 85(5). https://www.onlinelibrary.wiley.com/doi/10.1002/ana.25450

Reference

Title
AXO-Lenti-PD Gene Therapy Shows Benefits in 2 Advanced Parkinson’s Patients in Phase 1/2 Trial
Publication
Parkinson's News Today
Publication Date
March 14 2019
Authors
Lopes J
URL
Read Full Resource
Title
Magnetic Resonance Imaging-Guided Phase 1 Trial of Putanimal AADC Gene Therapy for Parkinson’s Disease
Publication
Ann Neurol
Publication Date
2019
Authors
Christine C, Bankiewicz K, Van Laar A, Richardson R, et al.
Volume & Issue
Volume 85, Issue 5
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
  • It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall…  
  • According to the Pharmaceutical Research and Manufacturers of America, because of medical research, the number of Americans with Alzheimer’s could decrease by 3 million in 2025.  
  • In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.  
  • A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.